Novavax, Inc. (NVAX)

150.00
17.00 13.00
NASDAQ
Prev Close 133.28
Open 144.00
Day Low/High 137.62 / 151.00
52 Wk Low/High 3.54 / 189.40
Volume 6.61M
Exchange NASDAQ
Shares Outstanding 61.28B
Market Cap 7.62B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: What Happens in a Bull Market Is That Stocks Move Up on Nothing

Jim Cramer: What Happens in a Bull Market Is That Stocks Move Up on Nothing

Isaac Newton's first lesson: An object in motion stays in motion with the same speed and in the same direction unless acted upon by an unbalanced force.

The Relevance of the Russell 2000

The Relevance of the Russell 2000

The performance of IWM is telling you that all is not well in the overall U.S. economy.

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers

Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.

Jim Cramer: How Do You Refute These Market Gains?

Jim Cramer: How Do You Refute These Market Gains?

This is pretty much exactly what you get when you have so much positive research.

These 3 Biotechs Have Decent Values

These 3 Biotechs Have Decent Values

One would need to use covered calls to initiate positions that provide a solid amount of downside protection.

Novavax and Its $1.6 Billion Award Just Got My Attention

Novavax and Its $1.6 Billion Award Just Got My Attention

The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.

Novavax Could Surprise on the Upside - No Bearish Divergences Yet

Novavax Could Surprise on the Upside - No Bearish Divergences Yet

Let's review the charts and indicators.

Count Me a Covid-19 Skeptic, Including When It Comes to a Vaccine

Count Me a Covid-19 Skeptic, Including When It Comes to a Vaccine

The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.

Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine

Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine

When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.

China Headline Risk, Valuation Station and a Workday Play

China Headline Risk, Valuation Station and a Workday Play

WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.

Merck Is All In With a Threefold Approach to Covid-19

Merck Is All In With a Threefold Approach to Covid-19

I've been long Merck for a long time, since way before this pandemic became part of our lives.

Floor Traders Return to NYSE, Novavax Vaccine News, Be Amphibious

Floor Traders Return to NYSE, Novavax Vaccine News, Be Amphibious

The return of NYSE floor traders is symbolic of the return to normalcy, as vaccine candidate manufacturers are scaling up for mass production.

Jim Cramer: It's Still Better to Be Safe Than Sorry

Jim Cramer: It's Still Better to Be Safe Than Sorry

Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.

Sell Signals, 'Operation Warp Speed,' Trading Notes

Sell Signals, 'Operation Warp Speed,' Trading Notes

Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.

Jim Cramer: Let the Froth Wash Out

Jim Cramer: Let the Froth Wash Out

Let's look at the stocks that will get crushed and that you can't touch right now.

Vaccine Maker Novavax Shares Have Soared but Can It Continue?

Vaccine Maker Novavax Shares Have Soared but Can It Continue?

The company has worked on two previous coronavirus vaccines as well as an Ebola vaccine.

Jim Cramer: The Cost of Staying Closed

Jim Cramer: The Cost of Staying Closed

We can't wait for a vaccine, but we can follow logical guidelines for staying as safe as possible, helping us avoid another Great Depression.

2 Picks, 2 Pans Among Small-Cap Biotechs Laboring in the Covid-19 Fields

2 Picks, 2 Pans Among Small-Cap Biotechs Laboring in the Covid-19 Fields

Quotient Limited and Redhill Biopharma could deliver for shareholders, while Novavax Inc. and Inovio Pharmaceuticals may not in the end.

This Isn't a Forgiving Environment, Long or Short

This Isn't a Forgiving Environment, Long or Short

It's not often you have both overnight and intraday gap risk, so be aware, and good luck out there.

Playing the Hand You're Dealt

Playing the Hand You're Dealt

Check out just a few of the year-to-date moves coming into Thursday on 8 companies you've never heard of before the last week or two.

Take a Poker Player's Approach to Playing Small Biotech Stocks

Take a Poker Player's Approach to Playing Small Biotech Stocks

As Kenny Rogers sang, you've got to know when to hold 'em and know when to fold 'em… and sometimes when not to play a hand at all.

Midday Report: Crude Stockpiles Rise for First Week in Nine; Stocks Rise

Midday Report: Crude Stockpiles Rise for First Week in Nine; Stocks Rise

Stocks move cautiously higher as investors wait for direction from a number of market-churning events tomorrow.

Novavax's Chart Looked Good, Until It Didn't

Novavax's Chart Looked Good, Until It Didn't

Things were looking up and then today happened.

Look to Costamare for Value in Shipping

Look to Costamare for Value in Shipping

It's safe to say these guys know what they are doing.

The Good, The Bad And The Ugly

"Such ingratitude, after all the times I saved your life." -- Blondie, THE GOOD THE BAD THE UGLY Let's run down the good, the bad and the ugly in today's market so far: THE GOOD Bonds are trading better today. The 10- and 30-year bond yields are dow...

Underlying Risks in Speculative Bio Techs Can't Be Overstated

I have followed Novavax for several years.   After yesterday's market close the company announced the results of their Phase Three trial for a respiratory-virus drug. NVAX missed its goal, and the shares are trading down by about 80% ($8.40 to $1) i...